Caption Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$43.1M Buy
847,800
+55,300
+7% +$2.58M 0.25% 82
2025
Q4
$23.4M Buy
792,500
+742,500
+1,485% +$20.2M 0.16% 149
2025
Q3
$1.29M Sell
50,000
-50,000
-50% -$1.39M 0.01% 1021
2025
Q2
$2.76M Hold
100,000
0.03% 615
2025
Q1
$2.83M Buy
+100,000
New +$3.55M 0.03% 577
2023
Q1
Sell
-20,000
Closed -$3.59M 1372
2022
Q4
$3.59M Buy
+20,000
New +$3.27M 0.06% 400
2021
Q4
Sell
-39,300
Closed -$15.1M 1819
2021
Q3
$15.1M Sell
39,300
-56,700
-59% -$20.9M 0.17% 149
2021
Q2
$22.6M Sell
96,000
-60,000
-38% -$10.7M 0.29% 63
2021
Q1
$20.4M Buy
156,000
+96,000
+160% +$13.9M 0.44% 37
2020
Q4
$6.27M Buy
60,000
+25,000
+71% +$2.53M 0.14% 184
2020
Q3
$2.48M Buy
+35,000
New +$2.44M 0.06% 372

Other funds holding MRNA

Caption Management's MRNA Position: Q4 2025 in Review

Caption Management sold out of Moderna (MRNA) in Q4 2025, closing a stake of 66,747 shares — an estimated $1.81M sold.

Caption Management first reported a position in MRNA in Q4 2020 and held it in 3 quarters. The position peaked at $3.06M in Q4 2020. 672 funds tracked by Wall St. Rank hold MRNA as of Q4 2025.

  • Caption Management reported no remaining Moderna position as of Q4 2025 after selling out during the quarter.
  • Caption Management sold 66,747 Moderna shares in Q4 2025, an estimated $1.81M.
  • Caption Management first reported a position in Moderna in Q4 2020 and held it in 3 quarters.
  • Caption Management's Moderna position peaked at $3.06M in Q4 2020.
  • 672 funds tracked by Wall St. Rank held Moderna as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.